Publications by authors named "C Brusko"
Background: Few studies have evaluated continuous glucose monitoring (CGM) in older patients with type 2 diabetes mellitus (T2DM) not using injectable therapy. CGM is useful for investigating hypoglycemia and glycemic variability, which is associated with complications in T2DM.
Methods: A CGM substudy of Individualized treatMent aPproach for oldER patIents in a randomized trial in type 2 diabetes Mellitus (IMPERIUM)) was conducted.
Article Synopsis
- - The study aimed to compare the effectiveness of two diabetes treatment strategies in older patients (≥65 years) who struggled to meet their blood sugar targets using diet, exercise, and oral medications.
- - Two treatment strategies were tested: Strategy-A focused on glucose-dependent therapies, while Strategy-B used non-glucose-dependent therapies, with no significant difference in achieving blood sugar goals between the two groups.
- - However, Strategy-A showed significantly lower rates of hypoglycaemia incidents, suggesting it may be a safer option for older, vulnerable patients with type 2 diabetes.
Three higher concentration insulin products (insulin lispro 200 units/mL, insulin degludec 200 units/mL, and insulin glargine 300 units/mL) received US Food and Drug Administration (FDA) approval in 2015. Although human regular insulin 500 units/mL (U-500) was approved in 1997, a pen and dedicated U-500 syringe became available in 2016. These products offer more treatment options for the increasing numbers of patients requiring insulin to achieve and maintain glycemic targets.
View Article and Find Full Text PDF